Media headlines about Corcept Therapeutics (NASDAQ:CORT) have trended somewhat positive on Sunday, according to Accern. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Corcept Therapeutics earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.3731751442415 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Volatility Factor under Trader’s Radar – Corcept Therapeutics Incorporated (NASDAQ: CORT) (stocktradingdesk.com)
- Lacking Vigorous Positions in Performance Measures: Corcept Therapeutics Incorporated (NASDAQ:CORT) (stockmarketstop.com)
- Risk Factors under Consideration – Corcept Therapeutics Incorporated (NASDAQ:CORT) (thestockgem.com)
- Focus on Technical Insights: Corcept Therapeutics Incorporated (CORT) (wallstreetmorning.com)
- Corcept Therapeutics Incorporated (CORT) stock reaches new 52-week High (thestocksnews.com)
Several research firms have recently weighed in on CORT. BidaskClub raised Corcept Therapeutics from a “hold” rating to a “buy” rating in a report on Friday. Seaport Global Securities began coverage on Corcept Therapeutics in a report on Friday, April 13th. They issued a “buy” rating and a $32.00 price objective for the company. B. Riley began coverage on Corcept Therapeutics in a report on Thursday, March 8th. They issued a “buy” rating and a $30.00 price objective for the company. Stifel Nicolaus decreased their price objective on Corcept Therapeutics from $25.00 to $20.00 and set a “buy” rating for the company in a report on Monday, February 5th. Finally, Piper Jaffray set a $30.00 price objective on Corcept Therapeutics and gave the company a “buy” rating in a report on Monday, February 5th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $24.33.
Shares of NASDAQ CORT opened at $17.59 on Friday. Corcept Therapeutics has a 1-year low of $8.90 and a 1-year high of $25.96. The firm has a market cap of $2,086.47, a P/E ratio of 39.98 and a beta of 1.88.
Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings results on Thursday, February 22nd. The biotechnology company reported $0.17 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.19 by ($0.02). Corcept Therapeutics had a return on equity of 53.35% and a net margin of 81.11%. The company had revenue of $53.30 million for the quarter, compared to analyst estimates of $53.30 million. During the same period in the prior year, the business earned $0.04 earnings per share. Corcept Therapeutics’s revenue for the quarter was up 123.9% compared to the same quarter last year. analysts anticipate that Corcept Therapeutics will post 0.96 EPS for the current year.
In related news, insider Robert S. Fishman sold 8,000 shares of the stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $15.67, for a total transaction of $125,360.00. Following the completion of the sale, the insider now directly owns 8,000 shares of the company’s stock, valued at $125,360. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Renee D. Gala purchased 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 7th. The shares were bought at an average cost of $15.51 per share, with a total value of $155,100.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $15,510. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 24,000 shares of company stock valued at $387,920. Corporate insiders own 19.20% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Corcept Therapeutics (CORT) Share Price” was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.thelincolnianonline.com/2018/04/22/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-corcept-therapeutics-cort-share-price.html.
Corcept Therapeutics Company Profile
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression.
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.